Share Price and Basic Stock Data
Last Updated: January 8, 2026, 5:07 pm
| PEG Ratio | -10.25 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Amrutanjan Health Care Ltd operates within the pharmaceuticals sector and has demonstrated a varied revenue trajectory over the past years. The company’s sales for the fiscal year ending March 2023 stood at ₹380 Cr, a decrease from ₹406 Cr in the previous fiscal year. However, projections for the upcoming fiscal year, as reported, indicate a rebound with anticipated sales of ₹421 Cr for March 2024 and ₹452 Cr for March 2025. The quarterly sales figures show fluctuations, with the most recent quarter ending September 2023 reporting sales of ₹99 Cr. This reflects a slight recovery from a low of ₹78 Cr in June 2023 but remains below the quarterly peak of ₹111 Cr in September 2022. The overall trend indicates a potential recovery trajectory, aligning with growth initiatives and market demand in the pharmaceuticals sector, which typically experiences a steady demand against economic cycles.
Profitability and Efficiency Metrics
Amrutanjan’s profitability metrics reflect a mixed performance, with a reported operating profit margin (OPM) of 14% for the latest fiscal year, down from 20% in March 2022. The net profit for the fiscal year 2023 was ₹40 Cr, translating to an earnings per share (EPS) of ₹13.63. The latest quarterly data shows a net profit of ₹7 Cr for September 2023, highlighting challenges in maintaining profitability amidst fluctuating sales. The company’s return on equity (ROE) stood at 16.5%, which is considered healthy in the pharmaceutical sector, while the return on capital employed (ROCE) was at 22.4%. These figures indicate effective capital utilization despite the recent decline in operating metrics. The cash conversion cycle (CCC) of -23 days signifies strong operational efficiency, as it indicates that the company recovers cash from sales before it needs to pay suppliers.
Balance Sheet Strength and Financial Ratios
Amrutanjan Health Care’s balance sheet exhibits strength, characterized by minimal borrowings of ₹2 Cr against reserves of ₹339 Cr, reflecting a solid capital base. The company’s total liabilities stood at ₹421 Cr, against total assets of ₹432 Cr, indicating a healthy asset-to-liability ratio. The interest coverage ratio (ICR) reported at an impressive 78.72x demonstrates the company’s robust ability to meet interest obligations, which is significantly higher than industry norms. The price-to-book value ratio (P/BV) of 6.85x suggests that the market values the company at a premium, which can be attributed to its brand strength and growth potential. Furthermore, the current ratio of 3.46x indicates strong liquidity, allowing the company to comfortably cover short-term obligations. However, the high P/BV ratio may also reflect market expectations that could be challenging to meet if growth slows.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Amrutanjan Health Care Ltd reveals a stable ownership structure, with promoters holding 46.52% as of September 2025. This represents a decline from previous quarters, suggesting some dilution of control but still reflecting strong promoter confidence in the company’s future. Foreign institutional investors (FIIs) hold 2.38%, while domestic institutional investors (DIIs) have increased their stake to 12.90%, indicating growing institutional interest. The public holding is at 38.16%, which, alongside a total of 47,954 shareholders, signifies a broad base of retail investors. The gradual increase in DII participation could be a positive signal, as institutional investors often conduct thorough analyses before committing capital. However, the decline in promoter shareholding may raise questions about long-term strategic direction, potentially affecting investor confidence.
Outlook, Risks, and Final Insight
The outlook for Amrutanjan Health Care Ltd appears cautiously optimistic, given the expected recovery in sales and profitability metrics in the coming fiscal years. However, risks persist, including the recent volatility in quarterly sales and declining profit margins, which could impact future earnings. Additionally, the pharmaceutical sector faces constant challenges from regulatory changes and competitive pressures. To capitalize on its strengths, such as a solid balance sheet and effective cash management, the company must focus on enhancing operational efficiency and maintaining robust sales growth. Stakeholders should closely monitor market conditions and operational performance, as any significant deviation in these areas may necessitate strategic adjustments. Overall, while Amrutanjan possesses a resilient business model, it must navigate these challenges effectively to sustain growth and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,407 Cr. | 404 | 479/192 | 91.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,534.77 Cr | 1,143.36 | 52.83 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 111 | 98 | 100 | 78 | 99 | 117 | 127 | 84 | 110 | 123 | 135 | 94 | 118 |
| Expenses | 95 | 85 | 87 | 71 | 92 | 95 | 111 | 80 | 96 | 99 | 118 | 86 | 101 |
| Operating Profit | 16 | 12 | 13 | 7 | 7 | 22 | 16 | 4 | 14 | 23 | 18 | 8 | 17 |
| OPM % | 14% | 12% | 13% | 9% | 7% | 18% | 13% | 4% | 12% | 19% | 13% | 9% | 14% |
| Other Income | 3 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 17 | 15 | 16 | 9 | 9 | 24 | 20 | 6 | 16 | 26 | 21 | 11 | 19 |
| Tax % | 27% | 26% | 23% | 26% | 26% | 26% | 30% | 27% | 26% | 26% | 27% | 26% | 27% |
| Net Profit | 13 | 11 | 13 | 7 | 7 | 17 | 14 | 5 | 12 | 19 | 15 | 8 | 14 |
| EPS in Rs | 4.37 | 3.66 | 4.34 | 2.40 | 2.37 | 6.04 | 4.72 | 1.60 | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 |
Last Updated: January 2, 2026, 12:37 pm
Below is a detailed analysis of the quarterly data for Amrutanjan Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 118.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Jun 2025) to 118.00 Cr., marking an increase of 24.00 Cr..
- For Expenses, as of Sep 2025, the value is 101.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 86.00 Cr. (Jun 2025) to 101.00 Cr., marking an increase of 15.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Jun 2025) to 17.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 14.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Jun 2025) to 14.00%, marking an increase of 5.00%.
- For Other Income, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 4.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Jun 2025) to 27.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Jun 2025) to 14.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.83. The value appears strong and on an upward trend. It has increased from 2.87 (Jun 2025) to 4.83, marking an increase of 1.96.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 131 | 154 | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 470 |
| Expenses | 108 | 130 | 143 | 178 | 192 | 222 | 231 | 258 | 326 | 335 | 369 | 394 | 404 |
| Operating Profit | 23 | 25 | 32 | 29 | 28 | 31 | 31 | 75 | 80 | 45 | 52 | 58 | 66 |
| OPM % | 18% | 16% | 18% | 14% | 13% | 12% | 12% | 22% | 20% | 12% | 12% | 13% | 14% |
| Other Income | 3 | 5 | 6 | 7 | 8 | 7 | 8 | 11 | 15 | 15 | 16 | 18 | 18 |
| Interest | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 |
| Profit before tax | 21 | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 62 | 69 | 77 |
| Tax % | 32% | 35% | 35% | 35% | 39% | 29% | 27% | 25% | 26% | 26% | 27% | 26% | |
| Net Profit | 15 | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 57 |
| EPS in Rs | 4.97 | 5.86 | 7.68 | 7.47 | 6.84 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.55 | 17.58 | 19.61 |
| Dividend Payout % | 32% | 30% | 25% | 26% | 22% | 26% | 24% | 20% | 20% | 34% | 30% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.33% | 29.41% | 0.00% | -9.09% | 25.00% | 0.00% | 144.00% | 9.84% | -40.30% | 12.50% | 13.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 16.08% | -29.41% | -9.09% | 34.09% | -25.00% | 144.00% | -134.16% | -50.13% | 52.80% | 0.83% |
Amrutanjan Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 4% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 15% |
| 3 Years: | -9% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | -1% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 20% |
| 3 Years: | 15% |
| Last Year: | 17% |
Last Updated: September 4, 2025, 11:10 pm
Balance Sheet
Last Updated: December 10, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 94 | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 286 | 324 | 339 |
| Borrowings | 6 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
| Other Liabilities | 22 | 25 | 28 | 34 | 38 | 42 | 44 | 57 | 84 | 70 | 77 | 93 | 88 |
| Total Liabilities | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 432 |
| Fixed Assets | 15 | 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | 49 | 49 |
| CWIP | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 2 | 17 | 1 | 2 | 16 | 26 |
| Investments | 14 | 14 | 10 | 10 | 8 | 18 | 18 | 18 | 13 | 5 | 0 | 0 | 0 |
| Other Assets | 95 | 100 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 315 | 356 | 357 |
| Total Assets | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 432 |
Below is a detailed analysis of the balance sheet data for Amrutanjan Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Reserves, as of Sep 2025, the value is 339.00 Cr.. The value appears strong and on an upward trend. It has increased from 324.00 Cr. (Mar 2025) to 339.00 Cr., marking an increase of 15.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing). It has decreased from 93.00 Cr. (Mar 2025) to 88.00 Cr., marking a decrease of 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 432.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 421.00 Cr. (Mar 2025) to 432.00 Cr., marking an increase of 11.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 49.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 49.00 Cr..
- For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 356.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 1.00 Cr..
- For Total Assets, as of Sep 2025, the value is 432.00 Cr.. The value appears strong and on an upward trend. It has increased from 421.00 Cr. (Mar 2025) to 432.00 Cr., marking an increase of 11.00 Cr..
Notably, the Reserves (339.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 17.00 | 25.00 | 32.00 | 27.00 | 28.00 | 31.00 | 29.00 | 74.00 | 79.00 | 44.00 | 50.00 | 56.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 62 | 55 | 51 | 46 | 47 | 37 | 19 | 34 | 32 | 42 | 45 |
| Inventory Days | 45 | 44 | 44 | 44 | 40 | 45 | 74 | 45 | 53 | 58 | 50 | 45 |
| Days Payable | 44 | 46 | 51 | 110 | 102 | 92 | 98 | 106 | 122 | 95 | 96 | 113 |
| Cash Conversion Cycle | 67 | 61 | 48 | -15 | -16 | 0 | 13 | -41 | -35 | -6 | -5 | -23 |
| Working Capital Days | 39 | 42 | 45 | 76 | 26 | 30 | 70 | 28 | 92 | 117 | 173 | 99 |
| ROCE % | 24% | 26% | 29% | 28% | 25% | 25% | 23% | 44% | 38% | 19% | 21% | 22% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 1,466,269 | 0.59 | 99.85 | 1,466,269 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential FMCG Fund | 713,715 | 2.48 | 48.6 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| Diluted EPS (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| Cash EPS (Rs.) | 16.43 | 16.37 | 12.51 | 10.98 | 9.47 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 86.22 | 74.40 | 64.97 | 61.06 | 56.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 86.22 | 74.40 | 64.97 | 61.06 | 56.29 |
| Revenue From Operations / Share (Rs.) | 153.25 | 127.77 | 113.97 | 96.97 | 94.18 |
| PBDIT / Share (Rs.) | 23.16 | 24.95 | 19.32 | 16.93 | 14.83 |
| PBIT / Share (Rs.) | 21.20 | 22.66 | 17.13 | 14.47 | 12.28 |
| PBT / Share (Rs.) | 22.75 | 22.36 | 16.64 | 13.26 | 10.59 |
| Net Profit / Share (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| NP After MI And SOA / Share (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| PBDIT Margin (%) | 15.11 | 19.52 | 16.95 | 17.46 | 15.75 |
| PBIT Margin (%) | 13.83 | 17.73 | 15.02 | 14.92 | 13.04 |
| PBT Margin (%) | 14.84 | 17.50 | 14.60 | 13.67 | 11.24 |
| Net Profit Margin (%) | 9.43 | 11.01 | 9.04 | 8.78 | 7.34 |
| NP After MI And SOA Margin (%) | 9.43 | 11.01 | 9.04 | 8.78 | 7.34 |
| Return on Networth / Equity (%) | 16.77 | 18.92 | 15.87 | 13.94 | 12.29 |
| Return on Capital Employeed (%) | 23.87 | 29.45 | 25.52 | 22.73 | 20.83 |
| Return On Assets (%) | 13.07 | 14.65 | 12.16 | 10.34 | 8.14 |
| Total Debt / Equity (X) | 0.01 | 0.02 | 0.02 | 0.08 | 0.18 |
| Asset Turnover Ratio (%) | 1.48 | 1.35 | 1.30 | 1.12 | 1.00 |
| Current Ratio (X) | 3.46 | 3.59 | 3.20 | 2.87 | 1.67 |
| Quick Ratio (X) | 3.15 | 3.27 | 2.87 | 2.55 | 1.40 |
| Inventory Turnover Ratio (X) | 7.67 | 7.09 | 6.93 | 6.06 | 5.44 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 27.34 | 33.93 | 37.58 | 43.33 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 23.52 | 27.97 | 29.14 | 31.67 |
| Earning Retention Ratio (%) | 0.00 | 72.66 | 66.07 | 62.42 | 56.67 |
| Cash Earning Retention Ratio (%) | 0.00 | 76.48 | 72.03 | 70.86 | 68.33 |
| Interest Coverage Ratio (X) | 78.72 | 83.47 | 39.72 | 14.01 | 8.75 |
| Interest Coverage Ratio (Post Tax) (X) | 43.91 | 48.10 | 22.20 | 8.05 | 5.08 |
| Enterprise Value (Cr.) | 817.64 | 564.15 | 663.81 | 156.21 | 169.76 |
| EV / Net Operating Revenue (X) | 3.65 | 3.02 | 3.99 | 1.10 | 1.23 |
| EV / EBITDA (X) | 24.16 | 15.47 | 23.51 | 6.31 | 7.83 |
| MarketCap / Net Operating Revenue (X) | 3.85 | 3.27 | 4.20 | 1.29 | 1.23 |
| Retention Ratios (%) | 0.00 | 72.65 | 66.06 | 62.41 | 56.66 |
| Price / BV (X) | 6.85 | 5.61 | 7.36 | 2.06 | 2.06 |
| Price / Net Operating Revenue (X) | 3.85 | 3.27 | 4.20 | 1.29 | 1.23 |
| EarningsYield | 0.02 | 0.03 | 0.02 | 0.06 | 0.05 |
After reviewing the key financial ratios for Amrutanjan Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 17, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 16) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For Diluted EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For Cash EPS (Rs.), as of Mar 17, the value is 16.43. This value is within the healthy range. It has increased from 16.37 (Mar 16) to 16.43, marking an increase of 0.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
- For Revenue From Operations / Share (Rs.), as of Mar 17, the value is 153.25. It has increased from 127.77 (Mar 16) to 153.25, marking an increase of 25.48.
- For PBDIT / Share (Rs.), as of Mar 17, the value is 23.16. This value is within the healthy range. It has decreased from 24.95 (Mar 16) to 23.16, marking a decrease of 1.79.
- For PBIT / Share (Rs.), as of Mar 17, the value is 21.20. This value is within the healthy range. It has decreased from 22.66 (Mar 16) to 21.20, marking a decrease of 1.46.
- For PBT / Share (Rs.), as of Mar 17, the value is 22.75. This value is within the healthy range. It has increased from 22.36 (Mar 16) to 22.75, marking an increase of 0.39.
- For Net Profit / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For NP After MI And SOA / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For PBDIT Margin (%), as of Mar 17, the value is 15.11. This value is within the healthy range. It has decreased from 19.52 (Mar 16) to 15.11, marking a decrease of 4.41.
- For PBIT Margin (%), as of Mar 17, the value is 13.83. This value is within the healthy range. It has decreased from 17.73 (Mar 16) to 13.83, marking a decrease of 3.90.
- For PBT Margin (%), as of Mar 17, the value is 14.84. This value is within the healthy range. It has decreased from 17.50 (Mar 16) to 14.84, marking a decrease of 2.66.
- For Net Profit Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
- For NP After MI And SOA Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
- For Return on Networth / Equity (%), as of Mar 17, the value is 16.77. This value is within the healthy range. It has decreased from 18.92 (Mar 16) to 16.77, marking a decrease of 2.15.
- For Return on Capital Employeed (%), as of Mar 17, the value is 23.87. This value is within the healthy range. It has decreased from 29.45 (Mar 16) to 23.87, marking a decrease of 5.58.
- For Return On Assets (%), as of Mar 17, the value is 13.07. This value is within the healthy range. It has decreased from 14.65 (Mar 16) to 13.07, marking a decrease of 1.58.
- For Total Debt / Equity (X), as of Mar 17, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 16) to 0.01, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 17, the value is 1.48. It has increased from 1.35 (Mar 16) to 1.48, marking an increase of 0.13.
- For Current Ratio (X), as of Mar 17, the value is 3.46. This value exceeds the healthy maximum of 3. It has decreased from 3.59 (Mar 16) to 3.46, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 17, the value is 3.15. This value exceeds the healthy maximum of 2. It has decreased from 3.27 (Mar 16) to 3.15, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 17, the value is 7.67. This value is within the healthy range. It has increased from 7.09 (Mar 16) to 7.67, marking an increase of 0.58.
- For Dividend Payout Ratio (NP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 27.34 (Mar 16) to 0.00, marking a decrease of 27.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.52 (Mar 16) to 0.00, marking a decrease of 23.52.
- For Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 72.66 (Mar 16) to 0.00, marking a decrease of 72.66.
- For Cash Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.48 (Mar 16) to 0.00, marking a decrease of 76.48.
- For Interest Coverage Ratio (X), as of Mar 17, the value is 78.72. This value is within the healthy range. It has decreased from 83.47 (Mar 16) to 78.72, marking a decrease of 4.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 17, the value is 43.91. This value is within the healthy range. It has decreased from 48.10 (Mar 16) to 43.91, marking a decrease of 4.19.
- For Enterprise Value (Cr.), as of Mar 17, the value is 817.64. It has increased from 564.15 (Mar 16) to 817.64, marking an increase of 253.49.
- For EV / Net Operating Revenue (X), as of Mar 17, the value is 3.65. This value exceeds the healthy maximum of 3. It has increased from 3.02 (Mar 16) to 3.65, marking an increase of 0.63.
- For EV / EBITDA (X), as of Mar 17, the value is 24.16. This value exceeds the healthy maximum of 15. It has increased from 15.47 (Mar 16) to 24.16, marking an increase of 8.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
- For Retention Ratios (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 72.65 (Mar 16) to 0.00, marking a decrease of 72.65.
- For Price / BV (X), as of Mar 17, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 5.61 (Mar 16) to 6.85, marking an increase of 1.24.
- For Price / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
- For EarningsYield, as of Mar 17, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 16) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Amrutanjan Health Care Ltd:
- Net Profit Margin: 9.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.87% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.77% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 43.91
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.15
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 32.1 (Industry average Stock P/E: 52.83)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | No.103 (Old No.42-45), Chennai (Madras) Tamil Nadu 600004 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Sambhu Prasad | Chairman & Managing Director |
| Mr. G Raghavan | Non Executive Director |
| Ms. Ramaa Prabhakar Arikirevula | Non Executive Director |
| Ms. Meenalochani Raghunathan | Ind. Non-Executive Director |
| Mr. Raja Venkataraman | Ind. Non-Executive Director |
| Mr. S Muralidharan | Ind. Non-Executive Director |
| Mr. V Nagaraj | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Amrutanjan Health Care Ltd?
Amrutanjan Health Care Ltd's intrinsic value (as of 08 January 2026) is ₹503.64 which is 20.06% lower the current market price of ₹630.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,819 Cr. market cap, FY2025-2026 high/low of ₹843/544, reserves of ₹339 Cr, and liabilities of ₹432 Cr.
What is the Market Cap of Amrutanjan Health Care Ltd?
The Market Cap of Amrutanjan Health Care Ltd is 1,819 Cr..
What is the current Stock Price of Amrutanjan Health Care Ltd as on 08 January 2026?
The current stock price of Amrutanjan Health Care Ltd as on 08 January 2026 is ₹630.
What is the High / Low of Amrutanjan Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Amrutanjan Health Care Ltd stocks is ₹843/544.
What is the Stock P/E of Amrutanjan Health Care Ltd?
The Stock P/E of Amrutanjan Health Care Ltd is 32.1.
What is the Book Value of Amrutanjan Health Care Ltd?
The Book Value of Amrutanjan Health Care Ltd is 118.
What is the Dividend Yield of Amrutanjan Health Care Ltd?
The Dividend Yield of Amrutanjan Health Care Ltd is 0.73 %.
What is the ROCE of Amrutanjan Health Care Ltd?
The ROCE of Amrutanjan Health Care Ltd is 22.4 %.
What is the ROE of Amrutanjan Health Care Ltd?
The ROE of Amrutanjan Health Care Ltd is 16.5 %.
What is the Face Value of Amrutanjan Health Care Ltd?
The Face Value of Amrutanjan Health Care Ltd is 1.00.